Ethics approval and consent to participate
This single-center, open-label phase 1 clinical trial was approved by the Clinical Research Committee and Human Ethics Committees of Shenzhen Hospital Southern Medical University and Shenzhen Geno-Immune Medical Institute. All procedures involving human participants were performed in accordance with the Declaration of Helsinki. Written informed consent was obtained from the patients or guardians before enrollment in the study.